223 related articles for article (PubMed ID: 36995071)
1. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
Islam MR; Osman OI; Hassan WMI
J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
[TBL] [Abstract][Full Text] [Related]
2. FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.
Egbuna C; Patrick-Iwuanyanwu KC; Onyeike EN; Khan J; Alshehri B
J Biomol Struct Dyn; 2022; 40(22):12248-12259. PubMed ID: 34486940
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD.
Bouback TA; Pokhrel S; Albeshri A; Aljohani AM; Samad A; Alam R; Hossen MS; Al-Ghamdi K; Talukder MEK; Ahammad F; Qadri I; Simal-Gandara J
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443556
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modeling Studies of
Ghosh S; Keretsu S; Cho SJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
[TBL] [Abstract][Full Text] [Related]
5. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
6. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
7. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
[TBL] [Abstract][Full Text] [Related]
8. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore-based virtual screening, molecular docking, and molecular dynamics studies for the discovery of novel FLT3 inhibitors.
Ouassaf M; Daoui O; Alam S; Elkhattabi S; Belaidi S; Chtita S
J Biomol Struct Dyn; 2023; 41(16):7712-7724. PubMed ID: 36106982
[TBL] [Abstract][Full Text] [Related]
10. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
Göring S; Bensinger D; Naumann EC; Schmidt B
ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
[TBL] [Abstract][Full Text] [Related]
11. The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.
Al-Subaie AM; Kamaraj B
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299222
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in FLT3 inhibitors for acute myeloid leukemia.
Tong L; Li X; Hu Y; Liu T
Future Med Chem; 2020 May; 12(10):961-981. PubMed ID: 32314599
[TBL] [Abstract][Full Text] [Related]
13. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
[TBL] [Abstract][Full Text] [Related]
14. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
15. Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.
Bultum LE; Tolossa GB; Lee D
PLoS One; 2022; 17(7):e0270050. PubMed ID: 35895695
[TBL] [Abstract][Full Text] [Related]
16. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
17. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
[TBL] [Abstract][Full Text] [Related]
18. FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia.
Gokhale P; Chauhan APS; Arora A; Khandekar N; Nayarisseri A; Singh SK
Bioinformation; 2019; 15(2):104-115. PubMed ID: 31435156
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.
Abutayeh RF; Taha MO
J Mol Graph Model; 2019 May; 88():128-151. PubMed ID: 30703688
[TBL] [Abstract][Full Text] [Related]
20. Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
Ko B; Jang Y; Kim MH; Lam TT; Seo HK; Jeong P; Choi M; Kang KW; Lee SD; Park JH; Kim M; Han SY; Kim YC
Eur J Med Chem; 2023 Dec; 262():115860. PubMed ID: 37866334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
